Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.

Journal of neurochemistry - 1 Oct 2005

Van Raamsdonk Jeremy M, Pearson Jacqueline, Bailey Craig D C, Rogers Daniel A, Johnson Gail V W, Hayden Michael R, Leavitt Blair R

Abstract excerpt

Huntington disease (HD) is an adult onset neurodegenerative disorder characterized by selective atrophy and cell loss within the striatum. There is currently no treatment that can prevent the striatal neuropathology. Transglutaminase (TG) activity is increased in HD patients, is associated with cell death, and has been suggested to contribute to striatal neuronal loss in HD. This work assesses the therapeutic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Corpus Striatum

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Administration Schedule

Share to Huntingtin Protein

Share to Huntington Disease

Share to Neuroprotective Agents

Share to Prosencephalon

Share to Transglutaminases

Source

Identifiers

PMID: 16181425
DOI: 10.1111/j.1471-4159.2005.03357.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease.PMID 16181425Read ↗

Screening of Therapeutic Strategies for Huntington's Disease in YAC128 Transgenic MiceSemantic proximity Read ↗

Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease.Semantic proximity Read ↗

Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.Semantic proximity Read ↗

Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington diseaseSemantic proximity Read ↗

Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington diseaseSemantic proximity Read ↗

Selective degeneration in YAC mouse models of Huntington disease.Semantic proximity Read ↗

In vivo Dopamine Efflux is Decreased in Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of Huntington's DiseaseSemantic proximity Read ↗

Age-dependent alterations of the kynurenine pathway in the YAC128 mouse model of Huntington disease.Semantic proximity Read ↗

Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.Semantic proximity Read ↗

Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 miceSemantic proximity Read ↗

Neurodegeneration in Huntington's disease involves loss of cystathionine γ-lyase.Semantic proximity Read ↗

Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.